Zhao He, Duan Li-Jun, Gao Yu-Shan, Yang Yong-Dong, Zhao Ding-Yan, Tang Xiang-Sheng, Hu Zhen-Guo, Li Chuan-Hong, Chen Si-Xue, Liu Tao, Yu Xing
Department of Orthopedics III, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, No. 5 Haiyuncang Street, Dongcheng District, Beijing, 100700, China.
Department of Orthopedics, Bayannaoer City Hospital, No. 98 Wulanbuhe Street, Lin He District, Bayannaoer, 015000, China.
J Orthop Surg Res. 2018 Mar 2;13(1):42. doi: 10.1186/s13018-018-0742-0.
Decompressive laminectomy (DI) is a standard operation for lumbar spinal stenosis (LSS) patient with severe claudication symptoms for many years. However, patients whose symptom severity does not meet undergoing invasive surgery make therapeutic options into dilemma. Interspinous spacers (ISP) bridge the gap between surgical interventions and CC in management of LSS. In our study, we aim to systematically assess the two FDA-approved interspinous spacers for treatment of lumbar spinal stenosis: Superion versus X-STOP.
Electronic databases, including PubMed, Embase, MEDLINE, Cochrane Library were searched to retrieve clinical trials concerning the comparison between Superion and X-STOP in treatment for lumbar spinal stenosis before April 2017. The following outcome measures were extracted: (1) Zurich Claudication Questionnaire (ZCQ) patient satisfaction score, (2) axial pain severity, (3) extremity pain severity, (4) back-specific functional impairment, (5) reoperation, and (6) complication. The data analysis was conducted with Review Manager 5.3.
Five randomized controlled trials (RCTs) with 1118 patients were included in this meta-analysis. The pooled analysis indicated that the Superion group is superior to X-STOP in axial pain severity (SMD: 0.03; 95% CI 0.15, 0.45; p < 0.0001, I = 41%, p = 0.16), ZCQ patient satisfaction score (SMD: 0.23; 95% CI 0.08, 0.38; p = 0.002, I = 0%, p = 0.61). However, Superion group showed similarity outcome in extremity pain severity (SMD: 0.18; 95% CI - 0.06, 0.43; p = 0.14, I = 62%, p = 0.05), back-specific functional impairment (SMD: 0.04; 95% CI - 0.10, 0.19; p = 0.56, I = 0%, p = 0.77), reoperation rate (RR: 1.10; 95% CI 0.82, 1.48; p = 0.51, I = 19%, p = 0.30), and complication (RR: 0.98; 95% CI 0.63, 1.53; p = 0.92, I = 0%, p = 0.83).
Both the Superion and X-STOP interspinous spacers can relieve symptoms of LSS. In addition, the Superion spacer may represent a promising spacer for patient with LSS. As we know, the effectiveness and safety of ISP is still considered investigational and unfavor clinical results in the medical literature may continue to limit the appeal of IPS to many surgeons in the future. However, because of the advantage of IPS technique, it will win a wide place in the future degenerative lumbar microsurgery.
多年来,减压性椎板切除术(DI)一直是治疗有严重跛行症状的腰椎管狭窄症(LSS)患者的标准手术。然而,症状严重程度不符合接受侵入性手术的患者,其治疗选择陷入两难境地。棘突间撑开器(ISP)在LSS的治疗中填补了手术干预和保守治疗之间的空白。在我们的研究中,我们旨在系统评估两种经美国食品药品监督管理局(FDA)批准的用于治疗腰椎管狭窄症的棘突间撑开器:Superion与X-STOP。
检索包括PubMed、Embase、MEDLINE、Cochrane图书馆在内的电子数据库,以获取2017年4月之前有关Superion和X-STOP治疗腰椎管狭窄症比较的临床试验。提取以下结局指标:(1)苏黎世跛行问卷(ZCQ)患者满意度评分,(2)轴向疼痛严重程度,(3)肢体疼痛严重程度,(4)背部特定功能障碍,(5)再次手术,以及(6)并发症。使用Review Manager 5.3进行数据分析。
本荟萃分析纳入了5项随机对照试验(RCT),共1118例患者。汇总分析表明,Superion组在轴向疼痛严重程度(标准化均数差:0.03;95%置信区间0.15,0.45;p<0.0001,I² = 41%,p = 0.16)、ZCQ患者满意度评分(标准化均数差:0.23;95%置信区间0.08,0.38;p = 0.002,I² = 0%,p = 0.61)方面优于X-STOP组。然而,Superion组在肢体疼痛严重程度(标准化均数差:0.18;95%置信区间 -0.06,0.43;p = 0.14,I² = 62%,p = 0.05)、背部特定功能障碍(标准化均数差:0.04;95%置信区间 -0.10,0.19;p = 0.56,I² = 0%,p = 0.77)、再次手术率(风险比:1.10;95%置信区间0.82,1.48;p = 0.51,I² = 19%,p = 0.30)和并发症(风险比:0.98;95%置信区间0.63,1.53;p = 0.92,I² = 0%,p = 0.83)方面显示出相似的结果。
Superion和X-STOP棘突间撑开器均可缓解LSS症状。此外,Superion撑开器可能是LSS患者一种有前景的撑开器。众所周知,ISP的有效性和安全性仍被视为试验性的,医学文献中不利的临床结果可能在未来继续限制许多外科医生对IPS的青睐。然而,由于IPS技术的优势,它将在未来的退行性腰椎显微手术中赢得广泛的应用。